Deepa Malieckal, MD
Internal Medicine · Brooklyn, NYNPI 1841516309
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 73.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $7,639, more than ten times the $25 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $1145.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$9K
- Alnylam Pharmaceuticals Inc.$3K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$130
- Travere Therapeutics, Inc.$25
What the payments were for
- Consulting fees$4,91539%
- Speaking & faculty fees$7,38559%
- Food & beverage$3022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $9,309 |
| Alnylam Pharmaceuticals Inc. | 2 | $3,138 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $130 |
| Travere Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,602 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $18,901 |
| Potassium Citrate ErPotassium Citrate | 108 | $13,137 |
| EliquisApixaban | 12 | $8,326 |
| Sevelamer Carbonate | 17 | $1,277 |
| Calcium Acetate | 28 | $1,003 |
| Losartan Potassium | 64 | $915 |
| Chlorthalidone | 35 | $828 |
| Nifedipine ErNifedipine | 42 | $751 |
| Amlodipine Besylate | 80 | $605 |
| Furosemide | 68 | $355 |
| Allopurinol | 39 | $284 |
| Hydralazine Hcl | 18 | $254 |
| Metoprolol Succinate | 16 | $217 |
| Indapamide | 13 | $207 |
| Labetalol Hcl | 14 | $188 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Jesi RamoneBrooklyn$627K
- Manish ParikhBrooklyn$236K
- Samuel UterBrooklyn$136K
- David DoveEast Hampton$12.3M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.